Table 2.
Maraviroc Switch Study Baseline Antiretroviral Therapy
| Characteristic | Control (n = 82) | MVC + 2 N(t)RTIs (n = 156) | MVC + PI/r (n = 157) | Total (N = 395) |
|---|---|---|---|---|
| N(t)RTI | ||||
| TDF/FTC | 38 (46.3) | 82 (52.6) | 83 (52.9) | 203 (51.4) |
| TDF/3TC | 13 (15.9) | 26 (16.7) | 25 (15.9) | 64 (16.2) |
| ABC/3TC | 18 (22.0) | 19 (12.2) | 20 (12.7) | 57 (14.4) |
| ZDV/3TC | 6 (7.3) | 20 (12.8) | 17 (10.8) | 43 (10.9) |
| Other | 7 (8.5) | 9 (5.6) | 12 (7.6) | 28 (7.1) |
| PI/r | ||||
| ATV/r | 27 (32.9) | 58 (37.2) | 55 (35.0) | 140 (35.4) |
| LPV/r | 29 (35.4) | 33 (21.2) | 50 (31.9) | 112 (28.4) |
| DRV/r | 13 (15.9) | 32 (20.5) | 20 (12.7) | 65 (16.5) |
| SQV/r | 9 (11.0) | 24 (15.4) | 22 (14.0) | 55 (13.92) |
| FPV/r | 4 (4.9) | 8 (5.1) | 10 (6.4) | 22 (5.6) |
| IDV/r | 0 (0.0) | 1 (0.6) | 0 (0.00) | 1 (0.3) |
Data are presented as No. (%).
Abbreviations: 3TC, lamivudine; ABC, abacavir; ATV/r, ritonavir-boosted atazanavir; DRV/r, ritonavir-boosted darunavir; FPV/r, ritonavir-boosted fosamprenavir; FTC, emtricitabine; IDV/r, ritonavir-boosted indinavir; LPV/r, ritonavir-boosted lopinavir; MVC, maraviroc; N(t)RTI, nucleoside/nucleotide reverse transcriptase inhibitor; PI/r, ritonavir-boosted protease inhibitor; SQV/r, ritonavir-boosted saquinavir; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.